CODX — Co-Diagnostics, Inc. Common Stock
NASDAQ · Healthcare · Medical Devices
$1.19
-$0.05 (-4.03%)
Co-Diagnostics, Inc. Common Stock (CODX) is a medical devices company listed on NASDAQ. It is led by Dwight H. Egan, based in 2401 S. Foothill Drive, Salt Lake City, UT, United States, 84109, with about 115 employees. Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
Latest reported CODX revenue for 2025-09-30 was $145.4K. Net income was -$5.9M. Revenue was down 10.8% from 2025-06-30 to 2025-09-30. CODX currently screens at market cap $31.4M.
Use this CODX page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CODX quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CODX SEC filings page. Lician reads the product cache first so this HTML stays unique to Co-Diagnostics, Inc. Common Stock even when a live quote feed is slow.
About Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.
CODX Key Statistics
Market Cap
$31.44M
Volume
315,999
Previous Close
$1.21
Day Range
$1.20 – $1.31
EPS
-$1.24
Revenue
$3.92M
Net Income
-$37.64M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
-42.5%
Profit Margin
-961.4%
Employees
115
CODX Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $3.92M | $6.81M | $34.22M | $97.89M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$37.64M | -$35.33M | -$14.24M | $36.66M |
| EPS (Diluted) | -$1.24 | -$1.20 | -$0.45 | $1.23 |
Total Assets
$64.00M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$2.94M
Operating Cash Flow
-$29.16M
Free Cash Flow
$0.00
Co-Diagnostics, Inc. Common Stock Company Information
- Chairman, CEO & President
- Dwight H. Egan
- Headquarters
- 2401 S. Foothill Drive, Salt Lake City, UT, United States, 84109
- Website
- co-dx.com
- Phone
- 801 438 1036
- IPO / Founded
- 2017-07-12
- Sector
- Healthcare
- Industry
- Medical Devices